The platelet-activating factor antagonist BN 52021 attenuates hypoxic- ischemic brain injury in the immature rat

Xiao Hong Liu, Baik-Lin Eun, Faye S. Silverstein, John D.E. Barks

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Platelet-activating factor (PAF) is overproduced in ischemic brain. Although postischemic PAF antagonist administration protects the mature brain in some models, little is known about the effects of PAF antagonists in the immature brain. We hypothesized that the PAF antagonist BN 52021 would attenuate perinatal cerebral hypoxic-ischemic injury. To elicit focal hypoxic-ischemic brain injury, 7-d-old (P7) rats (n = 111) underwent right carotid ligation, followed by 2.5-3.25 h of hypoxia (fractional concentration of inspired O2 = 0.08). BN 52021 neuroprotection was evaluated in three groups of experiments: 1) 25 mg/kg/dose, 0 and 2 h posthypoxia: 2), 25 mg/kg/dose immediately before and 1 h after hypoxia; and 3) posthypoxia- ischemia treatment with BN 52021 12.5, 25, or 50 mg/kg/dose in 2 doses 0 and 2 h after hypoxia. All experiments included concurrent vehicle-injected controls. To quantitate severity of injury, bilateral regional cross- sectional areas (groups 1 and 2) or hemisphere weights (group 3) were evaluated on P12. Both pre- and posthypoxic treatment with BN 52021 (25 mg/kg/dose, two serial doses) decreased the incidence of cerebral infarction from 90% to about 30% (p < 0.02, Fisher's exact test). Measurement of cross- sectional areas confirmed neuroprotection and indicated some benefit of pre- over posthypoxic ischemic treatment in hippocampus and cortex. Over the dose range tested, the neuroprotective effect of BN 52021 administration was not dose-dependent. In contrast, BN 52021 did not attenuate N-methyl-D-aspartate induced hippocampal excitotoxic injury in P7 rats. Either prophylactic or 'rescue' administration of PAF antagonists decreases the incidence and severity of brain injury associated with an episode of perinatal cerebral hypoxia-ischemia.

Original languageEnglish
Pages (from-to)797-803
Number of pages7
JournalPediatric Research
Volume40
Issue number6
DOIs
Publication statusPublished - 1996 Jan 1

Fingerprint

ginkgolide B
Platelet Activating Factor
Brain Injuries
Wounds and Injuries
Brain
Brain Hypoxia-Ischemia
Incidence
Cerebral Infarction
Neuroprotective Agents
N-Methylaspartate
Ligation
Hippocampus
Ischemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The platelet-activating factor antagonist BN 52021 attenuates hypoxic- ischemic brain injury in the immature rat. / Liu, Xiao Hong; Eun, Baik-Lin; Silverstein, Faye S.; Barks, John D.E.

In: Pediatric Research, Vol. 40, No. 6, 01.01.1996, p. 797-803.

Research output: Contribution to journalArticle

Liu, Xiao Hong ; Eun, Baik-Lin ; Silverstein, Faye S. ; Barks, John D.E. / The platelet-activating factor antagonist BN 52021 attenuates hypoxic- ischemic brain injury in the immature rat. In: Pediatric Research. 1996 ; Vol. 40, No. 6. pp. 797-803.
@article{9a5c49acb63b4e468d94c58d797c33dc,
title = "The platelet-activating factor antagonist BN 52021 attenuates hypoxic- ischemic brain injury in the immature rat",
abstract = "Platelet-activating factor (PAF) is overproduced in ischemic brain. Although postischemic PAF antagonist administration protects the mature brain in some models, little is known about the effects of PAF antagonists in the immature brain. We hypothesized that the PAF antagonist BN 52021 would attenuate perinatal cerebral hypoxic-ischemic injury. To elicit focal hypoxic-ischemic brain injury, 7-d-old (P7) rats (n = 111) underwent right carotid ligation, followed by 2.5-3.25 h of hypoxia (fractional concentration of inspired O2 = 0.08). BN 52021 neuroprotection was evaluated in three groups of experiments: 1) 25 mg/kg/dose, 0 and 2 h posthypoxia: 2), 25 mg/kg/dose immediately before and 1 h after hypoxia; and 3) posthypoxia- ischemia treatment with BN 52021 12.5, 25, or 50 mg/kg/dose in 2 doses 0 and 2 h after hypoxia. All experiments included concurrent vehicle-injected controls. To quantitate severity of injury, bilateral regional cross- sectional areas (groups 1 and 2) or hemisphere weights (group 3) were evaluated on P12. Both pre- and posthypoxic treatment with BN 52021 (25 mg/kg/dose, two serial doses) decreased the incidence of cerebral infarction from 90{\%} to about 30{\%} (p < 0.02, Fisher's exact test). Measurement of cross- sectional areas confirmed neuroprotection and indicated some benefit of pre- over posthypoxic ischemic treatment in hippocampus and cortex. Over the dose range tested, the neuroprotective effect of BN 52021 administration was not dose-dependent. In contrast, BN 52021 did not attenuate N-methyl-D-aspartate induced hippocampal excitotoxic injury in P7 rats. Either prophylactic or 'rescue' administration of PAF antagonists decreases the incidence and severity of brain injury associated with an episode of perinatal cerebral hypoxia-ischemia.",
author = "Liu, {Xiao Hong} and Baik-Lin Eun and Silverstein, {Faye S.} and Barks, {John D.E.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1203/00006450-199612000-00004",
language = "English",
volume = "40",
pages = "797--803",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The platelet-activating factor antagonist BN 52021 attenuates hypoxic- ischemic brain injury in the immature rat

AU - Liu, Xiao Hong

AU - Eun, Baik-Lin

AU - Silverstein, Faye S.

AU - Barks, John D.E.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Platelet-activating factor (PAF) is overproduced in ischemic brain. Although postischemic PAF antagonist administration protects the mature brain in some models, little is known about the effects of PAF antagonists in the immature brain. We hypothesized that the PAF antagonist BN 52021 would attenuate perinatal cerebral hypoxic-ischemic injury. To elicit focal hypoxic-ischemic brain injury, 7-d-old (P7) rats (n = 111) underwent right carotid ligation, followed by 2.5-3.25 h of hypoxia (fractional concentration of inspired O2 = 0.08). BN 52021 neuroprotection was evaluated in three groups of experiments: 1) 25 mg/kg/dose, 0 and 2 h posthypoxia: 2), 25 mg/kg/dose immediately before and 1 h after hypoxia; and 3) posthypoxia- ischemia treatment with BN 52021 12.5, 25, or 50 mg/kg/dose in 2 doses 0 and 2 h after hypoxia. All experiments included concurrent vehicle-injected controls. To quantitate severity of injury, bilateral regional cross- sectional areas (groups 1 and 2) or hemisphere weights (group 3) were evaluated on P12. Both pre- and posthypoxic treatment with BN 52021 (25 mg/kg/dose, two serial doses) decreased the incidence of cerebral infarction from 90% to about 30% (p < 0.02, Fisher's exact test). Measurement of cross- sectional areas confirmed neuroprotection and indicated some benefit of pre- over posthypoxic ischemic treatment in hippocampus and cortex. Over the dose range tested, the neuroprotective effect of BN 52021 administration was not dose-dependent. In contrast, BN 52021 did not attenuate N-methyl-D-aspartate induced hippocampal excitotoxic injury in P7 rats. Either prophylactic or 'rescue' administration of PAF antagonists decreases the incidence and severity of brain injury associated with an episode of perinatal cerebral hypoxia-ischemia.

AB - Platelet-activating factor (PAF) is overproduced in ischemic brain. Although postischemic PAF antagonist administration protects the mature brain in some models, little is known about the effects of PAF antagonists in the immature brain. We hypothesized that the PAF antagonist BN 52021 would attenuate perinatal cerebral hypoxic-ischemic injury. To elicit focal hypoxic-ischemic brain injury, 7-d-old (P7) rats (n = 111) underwent right carotid ligation, followed by 2.5-3.25 h of hypoxia (fractional concentration of inspired O2 = 0.08). BN 52021 neuroprotection was evaluated in three groups of experiments: 1) 25 mg/kg/dose, 0 and 2 h posthypoxia: 2), 25 mg/kg/dose immediately before and 1 h after hypoxia; and 3) posthypoxia- ischemia treatment with BN 52021 12.5, 25, or 50 mg/kg/dose in 2 doses 0 and 2 h after hypoxia. All experiments included concurrent vehicle-injected controls. To quantitate severity of injury, bilateral regional cross- sectional areas (groups 1 and 2) or hemisphere weights (group 3) were evaluated on P12. Both pre- and posthypoxic treatment with BN 52021 (25 mg/kg/dose, two serial doses) decreased the incidence of cerebral infarction from 90% to about 30% (p < 0.02, Fisher's exact test). Measurement of cross- sectional areas confirmed neuroprotection and indicated some benefit of pre- over posthypoxic ischemic treatment in hippocampus and cortex. Over the dose range tested, the neuroprotective effect of BN 52021 administration was not dose-dependent. In contrast, BN 52021 did not attenuate N-methyl-D-aspartate induced hippocampal excitotoxic injury in P7 rats. Either prophylactic or 'rescue' administration of PAF antagonists decreases the incidence and severity of brain injury associated with an episode of perinatal cerebral hypoxia-ischemia.

UR - http://www.scopus.com/inward/record.url?scp=0029852757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029852757&partnerID=8YFLogxK

U2 - 10.1203/00006450-199612000-00004

DO - 10.1203/00006450-199612000-00004

M3 - Article

C2 - 8947953

AN - SCOPUS:0029852757

VL - 40

SP - 797

EP - 803

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -